

**Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board  
Meeting by Zoom Webinar  
Wednesday, October 20, 2021 9 a.m. to 1:30 p.m.**

Agenda		
Time	Topic	Presenter
9 a.m.	<b>Welcome &amp; Introductions</b> <b>Pharmacy &amp; Therapeutics (P&amp;T) Committee Convenes (Reviews drug classes for the WA PDL)</b>	Ginni Buccola, Committee Chair
9:05 a.m.	Diabetes: Long-acting Insulin <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> <li>• Archive motion</li> </ul>	Heather Whitley, DERP
9:45 a.m.	Multiple Sclerosis	Beth Shaw, DERP
10:05 a.m.	<b>Pharmacy &amp; Therapeutics Committee Adjourns</b> <b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>	Ginni Buccola, Committee Chair
	Multiple Sclerosis Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• P&amp;T Motion</li> <li>• DUR Motion</li> </ul>	Umang Patel, Magellan
10:30 a.m.	<b>Break (10 min)</b>	All
10:40 a.m.	Antihyperlipidemics: <ul style="list-style-type: none"> <li>• Microsomal Triglyceride Transfer Protein (MTP) Inhibitor</li> <li>• PCSK-9 Inhibitors               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
10:55 a.m.	Antivirals: Influenza Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:05 a.m.	Cardiovascular Agents: Sinus Node Inhibitors <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:10 a.m.	Pituitary Suppressive Agents, LHRH <ul style="list-style-type: none"> <li>• Endocrine and Metabolic Agents: Pituitary Suppressants</li> <li>• Oncology Agents: LHRH Analogs – Injectable</li> </ul>	Umang Patel, Magellan

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul>	
11:25 a.m.	<b>Gastrointestinal Agents</b> <ul style="list-style-type: none"> <li>● Inflammatory Bowel Agents</li> <li>● Irritable Bowel Syndrome (IBS) Agents / GI Motility</li> <li>● Phosphate Binder Agents <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
11:40 a.m.	<b>Genitourinary Agents: Overactive Bladder Agents</b> <ul style="list-style-type: none"> <li>● Stakeholder input*</li> <li>● Motion</li> </ul>	Umang Patel, Magellan
11:55 a.m.	<b>Break (15 min)</b>	All
12:10 p.m.	<b>Hematological Agents: Hereditary Angioedema Agents</b> <ul style="list-style-type: none"> <li>● Stakeholder input*</li> <li>● Motion</li> </ul>	Umang Patel, Magellan
12:20 p.m.	<b>Miscellaneous Therapeutic Classes: Potassium Removing Agents</b> <ul style="list-style-type: none"> <li>● Stakeholder input*</li> <li>● Motion</li> </ul>	Umang Patel, Magellan
12:30 p.m.	<b>Substance Use Disorder:</b> <ul style="list-style-type: none"> <li>● Agents For Opioid Withdrawal</li> <li>● Opioid Antagonists</li> <li>● Opioid Partial Agonists – Subcutaneous</li> <li>● Opioid Partial Agonists – Transmucosal <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
12:50 p.m.	<b>Apple Health Policy: PCSK-9 Inhibitors</b> <ul style="list-style-type: none"> <li>● Stakeholder input*</li> <li>● Motion</li> </ul>	Ryan Taketomo, HCA
1:10 p.m.	<b>Drug Utilization Review Board Adjourns</b>	Ginni Buccola, Committee Chair

For all Apple Health (Medicaid) questions, please email [AppleHealthPolicy@hca.wa.gov](mailto:AppleHealthPolicy@hca.wa.gov)

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.



*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.